The new frontiers of longevity

Mario Abbadessa is Senior Managing Director, Head of Transactions Europe & Country Head of Hines Italy. He began his career in Hines in 2010, in 2016 he became responsible for the Group's activities in Italy, achieving real estate investments of almost €8 billion in Milan, Florence and Northern Italy, focusing focusing a long-term industrial strategy and building a solid portfolio of projects in residential, office, trophy assets and retail, logistics and data centres.

Full Professor of Occupational Medicine at the University of Milan and a leading expert in environmental epigenetics. As head of the Environmental Epigenetics Lab, her research explores how environmental factors influence epigenetic and molecular mechanisms and their connections to disease outcomes and health maintenance through life.

After graduating in Pharmacy, I started writing about medicine and health for the print media, while also carving out an experience on television as a science TV programs writer. Since 2002 I have been working as a science journalist at Sole 24 Ore.

Leading Angelini Ventures from 2022 with over 20 years of experience in venture capital, R&D and business development in companies such as Angelini Pharma, Novartis and Merck. He holds a PhD from Harvard University and an MBA from IE business school.

Dr. Sebastiano and his team developed ERA (Epigenetic Reprogramming of Aging), a breakthrough technology that rejuvenates adult cells while preserving their identity. His pioneering work earned prestigious awards, including the AFAR Junior Investigator Award, and has been featured in major media outlets like The New York Times and Nature Biotechnology.